SynAct Pharma, a clinical stage biotechnology company, agreed to acquire TXP Pharma, a privately owned Swiss-incorporated biotech company researching and developing pharmaceutical drugs, for $19m. “By combining the pipeline and scientific capabilities of SynAct and TXP, we strengthen SynAct’s leading position within therapies for resolution treatment through melanocortin biology, and boosts its growing development portfolio. Also, we can now tackle the full range of inflammatory and autoimmune diseases with two complementary platforms, which underscores SynAct’s place in the forefront of developing pharmaceuticals to treat these severe and debilitating diseases where there is a great unmet medical need," Uli Hacksell, SynAct Board Member.